Anixa Biosciences (NASDAQ:ANIX) Downgraded by Wall Street Zen to “Sell”

Anixa Biosciences (NASDAQ:ANIX) was downgraded by stock analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Separately, D. Boral Capital reissued a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a report on Wednesday, April 8th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.50.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.70 on Friday. The business’s fifty day simple moving average is $2.80 and its two-hundred day simple moving average is $3.23. Anixa Biosciences has a 12 month low of $2.44 and a 12 month high of $5.46. The company has a market cap of $90.53 million, a price-to-earnings ratio of -8.18 and a beta of 0.64.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Monday, March 9th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. As a group, research analysts forecast that Anixa Biosciences will post -0.38 EPS for the current year.

Hedge Funds Weigh In On Anixa Biosciences

A number of institutional investors have recently bought and sold shares of ANIX. Marshall Wace LLP bought a new position in Anixa Biosciences in the 2nd quarter worth $39,000. NewEdge Advisors LLC bought a new position in Anixa Biosciences in the 2nd quarter worth $33,000. Jane Street Group LLC raised its holdings in Anixa Biosciences by 37.2% in the 2nd quarter. Jane Street Group LLC now owns 41,800 shares of the company’s stock worth $138,000 after purchasing an additional 11,340 shares during the period. Benjamin Edwards Inc. bought a new position in Anixa Biosciences in the 2nd quarter worth $37,000. Finally, Vanguard Group Inc. raised its holdings in Anixa Biosciences by 2.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,422,342 shares of the company’s stock worth $4,694,000 after purchasing an additional 29,436 shares during the period. 29.13% of the stock is owned by institutional investors.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.